Skip to content
drillr.ai

INM

InMed Pharmaceuticals Inc.

NASDAQ · CAHealthcareBiotechnology
$1.52-1.30%

Price as of Jul 20, 2026

INM news

InMed Pharmaceuticals Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?

    Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible fo

    PR Newswire ·

  2. InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

    Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a wholly

    Newsfile Corp ·

  3. $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN PR Newswire NEW YORK, July 6, 2026 NEW YORK, July 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4725789-2&h=2196894249&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (https://edge.prnew

    PR Newswire ·

  4. Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?

    Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 12, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible

    PR Newswire ·

  5. $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—TMHC, NCSM, XOMA, and INM

    NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=Msne-XNkx7--T3Qq1RFGzvvTG_hdRRLZ4p67AjpywooZAhlUMiQQZGOkxTMQVNMlSME8BE-PxVraPXiAY0jA3qABxh_cX_jdJj-z6u4AKt68CU9gXIKR3ahYiJ7VbhL5FM5SYu-eyiZShJHkffC71MGQzfGSVpNLlQHlYwkp-i3UpZSk1xmqzfsafG3m66Wd7vl9AjNUwlSAlEMNCr3_Kg==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=0p2ES2KTGWNl3UFm4OHsnLkcZZL-0ajI4cwYitVL8bzOOGRfxyOwYFD-cxbjjHmrS0Pj3cFJgNkGjb6

    Globe Newswire ·

  6. InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

    Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq. As previously disclosed, the Company was notified by Nasd

    Newsfile Corp ·

  7. Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  8. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Taylor Morrison Home Corporation (NYSE - TMHC), Rallybio Corporation (Nasdaq – RLYB), InMed Pharmaceuticals, Inc. (Nasdaq – INM), KalVista Pharmaceuticals, Inc. (Nasdaq – KALV)

    BALA CYNWYD, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Taylor Morrison Home Corporation (NYSE - TMHC) Under the terms of the Merger Agreement, Taylor Morrison will be acquired by Berkshire Hathaway to acquire Taylor

    Globe Newswire ·

  9. Halper Sadeh LLC is Investigating Whether RAMP, NEE, INM, D are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  10. The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning The Merger—RAMP, NEE, D, and INM

    NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=uZ9xo4iEOiVmTIstzFxQaK9cL5Mz04bvaJk2EZStfUf8UiE3Bz79W47xKnw0DlF-hK_MC1X_oMZ9Qj10EuXnOq_KR1VX85G-tsi0bJzwje1OaTRvdA2O0zsWApiNnbYDssMyf3HDoxzyTCT3ojnc__i8lwYV9Mc2HH2Vwawzy9rEEAzmzpHYWtZkw6Bs8JadC-fcY4qkZqFImDhf_wxaPw==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=-BoaVHwG3EuYcbl0pGG0sSF_tgF3kK48L4ACu_QM-wktFF8S4H8XXhi4QU8KvO08rczqPeMpHZgLEyABp

    Globe Newswire ·

  11. Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?

    Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 28, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for

    PR Newswire ·

  12. SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM PR Newswire NEW YORK, May 28, 2026 NEW YORK, May 28, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4698844-2&h=2893635758&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (https://edge.prnewsw

    PR Newswire ·

  13. Halper Sadeh LLC is Investigating Whether D, AVB, INM, EQR are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  14. $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT

    NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=gpfZ4MWGZKJm2HblP27txLq2vQ7cUjhLH0hzh9rOkhQUkI2D5wQP0C6rPCvYwzRuKD8KNS_gFTTeHSY_PG7052BLNqimVBStAev57EDd0v0dd8k3KaWMC7RI5ney70cgfW8FBtbyptRUInp8zJLaNAkhImjSlZ3eXHVz9XxkaY75tBGdmrBEjFywUj7bKXXAR6wdAGr4WO-GppFwZb1TrQ==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=HoXVQcJ8W5Yjp92RTxXeaLQcO9Wpdafy_6qft4JelL9sSToSDO7v0lZPqMW-hC8BWXdTJxioQuDX8n3_k

    Globe Newswire ·

  15. Halper Sadeh LLC is Investigating Whether SEM, WSR, INM, GDOT are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  16. $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)

    NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=-M4Jy6Q5X6cFvBx9zVminAn5k9KQMTddVuvUV0n4enrBxD3Zx_FVb5wlZaf2XOfCRUltUgxDuqDHM4TmT53uG6kc3oKG47qsG4DS86jgRJuGWrg2puVTCiGIsFLqr8xtN8w__4deB1F_76fjRMzuhbho1wXV9eOuJOTS1odLD6kkLXXK-0x49ovHZT7OS-c0Ledu3M3R0cDZzMZIDlBRUw==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=lNn_IvnnshC0VZ2GpeStRd8t1r9rKIDVesbNGObcRauhDr3yU30OCvUfEDxLaaIojoGNmNBuxBPdoH5Xz

    Globe Newswire ·

  17. SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)

    BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (Nasdaq – INM) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Mentari Therapeutics, Inc. InMed shareholders are expected to own approximately 1.51% of the combined company. The investigation c

    Globe Newswire ·

  18. /C O R R E C T I O N -- InMed Pharmaceuticals/

    /C O R R E C T I O N -- InMed Pharmaceuticals/ PR Newswire VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 In the news release, InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies, issued 19-May-2026 by InMed Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advan

    PR Newswire ·

  19. INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

    INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you

    Business Wire ·

  20. InMed Pharmaceuticals Amends Preferred Investment Options

    Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. ("Armistice") in respect of certain outstanding preferred investment options held by Armistice. As previously report

    Newsfile Corp ·